A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of rHIgM22 in Patients with Multiple Sclerosis.
- Type of Study
- Neuroscience - Multiple Sclerosis
- Short Description
To evaluate the safety and tolerability of single ascending doses of rHIgM22 in patients with Multiple Sclerosis.
- Principal Investigator
- James Bowen, MD
- Eligibility Notes
Adult men and women between 18 and 70 years of age with no MS relapses within 30 days prior to screening and no treatment with corticosteroids, except for topical preparations, within 30 days prior to screening.
- Contact Name
- Yuriko Courtney and Beena Gangadharan
- Alternate Phone
- Alternate Email